<DOC>
	<DOCNO>NCT01973218</DOCNO>
	<brief_summary>The purpose study assess immunogenicity safety two dos Novartis Meningococcal B Recombinant ( rMenB+OMV NZ ) vaccine administer one month apart ( 0 , 1 month schedule ) Korean adolescent age 11 17 year .</brief_summary>
	<brief_title>Safety Immunogenicity Study Two Doses Novartis Meningococcal Serogroup B Recombinant Vaccine Adolescents Aged 11-17 Years .</brief_title>
	<detailed_description />
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Adolescents 1117 year age inclusive give write assent whose parent legal guardian give write informed consent time enrollment ; 2 . Available visit schedule study ( i.e . plan leave area end study period ) ; 3 . In good health determine outcome medical history , physical examination clinical judgment investigator ; 4 . With negative urine pregnancy test ( female subject ) . 1 . History meningococcal vaccine administration ; 2 . Current previous , confirm suspected disease cause N. meningitidis ; 3 . Household contact and/or intimate exposure individual laboratory confirm N. meningitidis infection within 60 day enrollment ; 4 . Pregnancy nursing ( breastfeed ) mother ; 5 . Female subject use plan use acceptable birth control measure , 2 month duration study ; 6 . Any serious chronic progressive disease ; 7 . Family member household member research staff ; 8 . Any condition opinion investigator may interfere evaluation study objective ; 9 . Significant acute chronic infection within previous 7 day fever within 3 day prior enrolment ; 10 . Antibiotics within 6 day prior enrollment ; 11 . Known suspected impairment/alteration immune system , immunosuppressive therapy ; 12 . Receipt blood , blood product and/or plasma derivative , parenteral immunoglobulin preparation within previous 90 day ; 13 . History severe allergic reaction previous vaccination hypersensitivity vaccine component ; 14 . Receipt intent immunize vaccine ( ) within 30 day prior throughout study period ; 15 . Participation another clinical trial within last 90 day plan study .</criteria>
	<gender>All</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Meningitis , adolescent , Meningococcal B</keyword>
</DOC>